ianalumab   Click here for help

GtoPdb Ligand ID: 10656

Synonyms: VAY-736 | VAY736
Immunopharmacology Ligand
Compound class: Antibody
Comment: Ianalumab (VAY736) is an investigtional anti-BAFF receptor (TNFRSF13C) monoclonal antibody (mAb) from Novartis. BLAST analysis of peptide sequences from its INN record reveal identical matches with peptide sequences claimed in Novartis patent WO2010007082A1 [2]. The sequence matches suggest that mAb MORO7347 identified in the patent could be VAY736.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Immunopharmacology Comments
Ianalumab (VAY736) was designed to target the BAFF receptor and competitively inhibit binding of BAFF ligand, and to thereby block BAFF receptor-mediated signalling and the downstream survival pathway in B cells. In addition, it was engineered (by defucosylating carbohydrate modifications on the Fc chain) to enhance antibody-dependent cellular cytotoxicity (ADCC) so as to maximally deplete circulating B cells. Pro-B and pre-B cells are BAFF receptor negative so are not directly affected by ianalumab. Ianalumab targets the receptor, which is in contrast to other BAFF agents which target the ligand (e.g. the approved antibody belimumab, tibulizumab, tabalumab, and the BAFF ligand-sequestering peptides blisibimod and atacicept).